Additionally, while the ICC allows a diagnosis of AML with CEBPA mutation with ≥10% blasts (similar to other genetically-defined AML, discussed above), the WHO-HAEM5 requires 20%, since the rare cases of bZIP CEBPA-mutated disease presenting with < 20% blasts have not been well studied. Here, CEBPA is linked to intrahepatic cholangiocarcinoma.